The Chemical Biology of Human Metallo-β-Lactamase Fold Proteins

Trends in Biochemical Sciences

Volumn 41, Issue 4, 2016, Pages 338-355

  Pettinati, Ilaria ^a   Brem, Jürgen ^a   Lee, Sook Y ^b   McHugh, Peter J ^b   Schofield, Christopher J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

DNA repair; hydrogen sulphide metabolism; metallo lactamase fold protein; nuclease; RNA processing; lactam antibiotic and cancer drug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CISPLATIN; CMAH PROTEIN; CPSF73 PROTEIN; ETHE1 PROTEIN; HYDROXYACYLGLUTATHIONE HYDROLASE; METALLO BETA LACTAMASE; MITOMYCIN; NAPE PLD PROTEIN; NUCLEASE; OXYGENASE; PHOSPHOLIPASE D; UNCLASSIFIED DRUG; ZINC ION; BETA LACTAM; BETA LACTAMASE; DCLRE1B PROTEIN, HUMAN; DNA LIGASE; ETHE1 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; MUSCLE PROTEIN; NUCLEAR PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PNKD PROTEIN, HUMAN; PROTEIN BINDING; THIOL ESTER HYDROLASE; ZINC;

ANTIBIOTIC RESISTANCE; BIOLOGICAL ACTIVITY; CATALYSIS; DETOXIFICATION; DNA REPAIR; DRUG RESISTANCE; DRUG TARGETING; ENZYME BINDING; ENZYME STRUCTURE; HUMAN; HYDROLYSIS; METAL BINDING; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN RNA BINDING; REVIEW; ALPHA HELIX; ARABIDOPSIS; BACTERIUM; BETA SHEET; CHEMISTRY; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; PROTEIN DOMAIN;

ARABIDOPSIS; BACTERIA; BETA-LACTAMASES; BETA-LACTAMS; DNA REPAIR ENZYMES; GENE EXPRESSION; HUMANS; HYDROLYSIS; MITOCHONDRIAL PROTEINS; MUSCLE PROTEINS; NUCLEAR PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION, ALPHA-HELICAL; PROTEIN CONFORMATION, BETA-STRAND; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; THIOLESTER HYDROLASES; ZINC;

EID: 84955494576     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.12.007     Document Type: Review

References (118)

1. Bush, K., Fisher, J.F., Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu. Rev. Microbiol. 65 (2011), 455–478.
2. Cornaglia, G., et al. Metallo-β-lacatamases: a last frontier for β-lactams?. Lancet Infect. Dis. 11 (2011), 381–393.
3. Bush, K., Proliferation and significance of clinically relevant beta-lactamases. Ann. N. Y. Acad. Sci. 1277 (2013), 84–90.
4. Drawz, S.M., et al. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother. 58 (2014), 1835–1846.
5. Carfi, A., et al. The 3-D structure of a zinc metallo-β-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J. 14 (1995), 4914–4921.
6. Crowder, M.W., et al. Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc. Chem. Res. 39 (2006), 721–728.
7. Bebrone, C., Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem. Pharmacol. 74 (2007), 1686–1701.
8. Daiyasu, H., et al. Expansion of the zinc metallo-hydrolase family of the beta-lactamase fold. FEBS Lett. 503 (2001), 1–6.
9. Baier, F., Tokuriki, N., Connectivity between catalytic landscapes of the metallo-β-lactamase superfamily. J. Mol. Biol. 426 (2014), 2442–2456.
10. Kabil, O., Banerjee, R., Characterization of patient mutations in human persulfide dioxygenase (ETHE1) involved in H2S catabolism. J. Biol. Chem. 287 (2012), 44561–44567.
11. Ishiai, M., et al. DNA cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus formation. Mol. Cell. Biol. 24 (2004), 10733–10741.
12. Wenzel, N.F., et al. The binding of iron and zinc to glyoxalase II occurs exclusively as di-metal centers and is unique within the metallo-beta-lactamase family. J. Biol. Inorg. Chem. 9 (2004), 429–438.
13. Xue, M., et al. Glyoxalase in ageing. Semin. Cell. Dev. Biol. 22 (2011), 293–301.
14. Ridderström, M., et al. Molecular cloning, heterologous expression, and characterization of human glyoxalase II. J. Biol. Chem. 271 (1996), 319–323.
15. Crowder, M.W., et al. Glyoxalase II from A. thaliana requires Zn (II) for catalytic activity. FEBS Lett. 418 (1997), 351–354.
16. Cameron, A.D., et al. Crystal structure of human glyoxalase II and its complex with a glutathione thiolester substrate analogue. Structure 7 (1999), 1067–1078.
17. Schilling, O., et al. Flexible metal binding of the metallo-beta-lactamase domain: glyoxalase II incorporates iron, manganese, and zinc in vivo. Biochem. 42 (2003), 11777–11786.
18. Fast, W., Sutton, L.D., Metallo-β-lactamase: inhibitors and reporter substrates. Biochim. Biophys. Acta 1834 (2013), 1648–1659.
19. Liénard, B.M.R., et al. Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols. Org. Biomol. Chem. 6 (2008), 2282–2294.
20. Tiranti, V., et al. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am. J. Hum. Genet. 74 (2004), 239–252.
21. Tiranti, V., et al. ETHE1 mutations are specific to ethylmalonic encephalopathy. J. Med. Genet. 43 (2006), 340–346.
22. Tiranti, V., et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat. Med. 15 (2009), 200–205.
23. Henriques, B.J., et al. Ethylmalonic encephalopathy ETHE1 R163W/R163Q mutations alter protein stability and redox properties of the iron centre. PLoS ONE, 9, 2014, e107157.
24. Tiranti, V., et al. ETHE1 mutations are specific to ethylmalonic encephalopathy. J. Med. Genet. 43 (2005), 340–346.
25. Mineri, R., et al. Identification of new mutations in the ETHE1 gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy. J. Med. Genet. 45 (2008), 473–478.
26. Higashitsuji, H., et al. A novel protein overexpressed in hepatoma accelerates export of NF-κB from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell 2 (2002), 335–346.
27. Higashitsuji, H., et al. Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1. J. Biol. Chem. 282 (2007), 13716–13725.
28. Suzuki, T., Miyata, N., Non-hydroxamate histone deacetylase inhibitors. Curr. Med. Chem. 12 (2005), 2867–2880.
29. McCoy, J.G., et al. Structure of an ETHE1-like protein from Arabidopsis thaliana. Acta. Crystallogr. D Biol. Crystallogr. 62 (2006), 964–970.
30. Pettinati, I., et al. Crystal structure of human persulfide dioxygenase: structural basis of ethylmalonic encephalopathy. Hum. Mol. Genet. 24 (2015), 2458–2469.
31. Hamed, R.B., et al. The enzymes of β-lactam biosynthesis. Nat. Prod. Rep. 30 (2013), 21–107.
32. Lee, H.Y., The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum. Mol. Genet. 13 (2004), 3161–3170.
33. Rainier, S., et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch. Neurol. 61 (2004), 1025–1029.
34. Shen, Y., et al. Mutations in PNKD causing paroxysmal dyskinesia alters protein cleavage and stability. Hum. Mol. Genet. 20 (2011), 2322–2332.
35. Pons, R., Paroxysmal non-kinesigenic dyskinesia due to a PNKD recurrent mutation: report of two Southern European families. Eur. J. Paediatr. Neurol. 16 (2012), 86–89.
36. Lee, H.Y., et al. Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. J. Clin. Invest. 122 (2012), 507–518.
37. Surmeier, D.J., et al. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 30 (2007), 228–235.
38. van der Stelt, M., Di Marzo, V., The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480 (2003), 133–150.
39. Kreitzer, A.C., Malenka, R.C., Striatal plasticity and basal ganglia circuit function. Neuron 60 (2008), 543–554.
40. Li, T.B., et al. Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle. Acta Biochim. Biophys. Sin. (Shanghai) 36 (2004), 412–418.
41. Ren, K., et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2(MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J. Biol. Chem. 283 (2008), 35598–35605.
42. Lu, R., et al. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer, 11, 2011, 270.
43. Dominski, Z., Nucleases of the metallo-beta-lactamase family and their role in DNA and RNA metabolism. Crit. Rev. Biochem. Mol. Biol. 42 (2007), 67–93.
44. Aravind, L., et al. Conserved domains in DNA repair proteins and evolution of repair systems. Nuc. Acids Res. 27 (1999), 1223–1242.
45. Callebaut, I., et al. Metallo-β-lactamase fold within nucleic acids processing enzymes: the beta-CASP family. Nuc. Acid Res. 30 (2002), 3592–3601.
46. Munari, F.M., et al. New features on Pso2 protein family in DNA interstrand cross-link repair 4 and in the maintenance of genomic integrity in Saccharomyces cerevisiae. Fungal Genet. Biol. 60 (2013), 122–132.
47. Yan, Y., et al. The multifunctional SNM1 gene family: not just nucleases. Future Oncol. 6 (2011), 1015–1029.
48. Sengerova, B., et al. Characterisation of the human SNM1A and SNM1B/Apollo DNA repair exonucleases. J. Biol. Chem. 287 (2012), 26254–26267.
49. Hazrati, A., et al. Human SNM1A suppresses the DNA repair defects of yeast Pso2 mutants. DNA Repair (Amst). 7 (2008), 230–238.
50. Ye, J., et al. TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell 142 (2010), 230–242.
51. Wang, A.T., et al. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev. 25 (2011), 1859–1870.
52. Akhter, S., Legerski, R.J., SNM1A acts downstream of ATM to promote the G1 cell cycle checkpoint. Biochem. Biophys. Res. Commun. 377 (2008), 236–241.
53. Lam, Y.C., et al. SNM1B/Apollo protects leading-strand telomeres against NHEJ-mediated repair. EMBO J. 29 (2010), 2230–2241.
54. Bae, J.B., et al. Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links. Oncogene 27 (2008), 5045–5056.
55. Demuth, I., et al. Human SNM1B is required for normal cellular response to both DNA interstrand crosslink-inducing agents and ionizing radiation. Oncogene 23 (2004), 8611–8618.
56. Mason, J.M., Sekiguchi, M.J., Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks. Hum. Mol. Genet. 20 (2011), 2549–2559.
57. Moshous, D., et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum. Mol. Genet. 9 (2000), 583–588.
58. Li, S., et al. Evidence that the DNA endonuclease ARTEMIS also has intrinsic 5′-exonuclease activity. J. Biol. Chem. 289 (2014), 7825–7834.
59. Ma, Y., et al. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108 (2002), 781–794.
60. De Ioannes, P., et al. Structural basis of DNA ligase IV-Artemis interaction in nonhomologous end-joining. Cell Rep. 2 (2012), 1505–1512.
61. Yan, Y., et al. Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27. Cell Cycle 10 (2011), 4098–4109.
62. Vogel, A., et al. The tRNase Z family of proteins: physiological functions, substrate specificity and structural properties. Biol. Chem. 386 (2005), 1253–1264.
63. Takahashi, M., et al. Regulation of the human tRNA Zs gene expression. FEBS Lett. 582 (2008), 2532–2536.
64. Bogenhagen, D.F., et al. Initial steps in RNA processing and ribosome assembly occur at mitochondrial DNA nucleoids. Cell Metab. 19 (2014), 618–629.
65. Brzezniak, L.K., et al. Involvement of human ELAC2 gene product in 3′ end processing of mitochondrial tRNAs. RNA Biol. 8 (2011), 616–626.
66. Haack, T.B., et al. ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy. Am. J. Hum. Genet. 93 (2013), 211–223.
67. Schiffer, S., et al. Assigning a function to a conserved group of proteins: the tRNA 3′- processing enzymes. EMBO J. 21 (2002), 2769–2777.
68. Rossmanith, W., Localization of human RNase Z isoforms: dual nuclear/mitochondrial targeting of the ELAC2 gene product by alternative translation initiation. PLoS ONE, 6, 2011, 19152.
69. Tavtigian, S.V., et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27 (2001), 172–180.
70. Takaku, H., et al. A candidate prostate cancer susceptibility gene encodes tRNA 3′ processing endoribonuclease. Nuc. Acids Res. 31 (2003), 2272–2278.
71. Alvarez-Cubero, M.J., et al. Prognostic role of genetic biomarkers in clinical progression of prostate cancer. Exp. Mol. Med., 47, 2015, e176.
72. Korver, W., et al. The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex. Int. J. Cancer 104 (2003), 283–288.
73. Shi, Y., Manley, J.L., The end of the message: multiple protein-RNA interactions define the mRNA polyadenylation site. Genes Dev. 29 (2015), 889–897.
74. Mandel, C.R., et al. Polyadenylation factor CPSF-73 is the pre-mRNA 3′-end-processing endonuclease. Nature 444 (2006), 953–956.
75. Yang, X., et al. Studies of the 5′ exonuclease and endonuclease activities of CPSF-73 in histone pre-mRNA processing. Mol. Cell. Biol. 29 (2009), 31–42.
76. Kolev, N.G., et al. Conserved motifs in both CPSF73 and CPSF100 are required to assemble the active endonuclease for histone mRNA 3′-end maturation. EMBO Rep. 9 (2008), 1013–1018.
77. Sullivan, K.D., et al. A core complex of CPSF73 CPSF100, and Symplekin may form two different cleavage factors for processing of poly (A) and histone mRNAs. Mol. Cell 34 (2009), 322–332.
78. Baillat, D., Wagner, E.J., Integrator: surprisingly diverse functions in gene expression. Trends Biochem. Sci. 40 (2015), 257–264.
79. Skaar, J.R., et al. The Integrator complex controls the termination of transcription at diverse classes of gene targets. Cell Res. 25 (2015), 288–305.
80. Dominski, Z., et al. A CPSF-73 homologue is required for cell cycle progression but not cell growth and interacts with a protein having features of CPSF-100. Mol. Cell. Biol. 25 (2005), 1489–1500.
81. Albrecht, T.R., Wagner, E.J., snRNA 3′ end formation requires heterodimeric association of integrator subunits. Mol. Cell. Biol. 32 (2012), 1112–1123.
82. Ueda, N., et al. N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: a novel enzyme of the beta-lactamase fold family releasing anandamide and other N-acylethanolamines. Life Sci. 77 (2005), 1750–1758.
83. Wang, J., et al. Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family. J. Biol. Chem. 281 (2006), 12325–12335.
84. Okamoto, Y., et al. Biosynthetic pathways of the endocannabinoid anandamide. Chem. Biodiv. 4 (2007), 1842–1857.
85. Guo, Y., et al. N-acylphosphatidylethanolamine-hydrolyzing phospholipase D Is an Important determinant of uterine anandamide levels during implantation. J. Biol. Chem. 280 (2005), 23429–23432.
86. Geurts, L., et al. Adipose tissue NAPE–PLD controls fat mass development by altering the browning process and gut microbiota. Nat. Commun., 6, 2015, 6495.
87. Magotti, P., et al. Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. Structure 23 (2015), 598–604.
88. Scott, S.A., et al. Discovery of Desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes. ACS Chem. Biol. 10 (2014), 421–432.
89. Varki, A., Multiple changes in sialic acid biology during human evolution. Glycoconj. J. 26 (2009), 231–245.
90. Chou, H.H., et al. Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 11736–11741.
91. Hayakawa, T., et al. Fixation of the human-specific CMP-N-acetylneuraminic acid hydroxylase pseudogene and implications of haplotype diversity for human evolution. Genetics 172 (2006), 1139–1146.
92. Martin, M.J., et al. Evolution of human-chimpanzee differences in malaria susceptibility: relationship to human genetic loss of N-glycolylneuraminic acid. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 12819–12824.
93. Deng, L., et al. Host adaptation of a bacterial toxin from the human pathogen Salmonella Typhi. Cell 159 (2014), 1290–1299.
94. Nystedt, J., et al. Human CMP-N-acetylneuraminic acid hydroxylase is a novel stem cell marker linked to stem cell-specific mechanisms. Stem Cells 28 (2010), 258–267.
95. Kavaler, S., et al. Pancreatic beta-cell failure in obese mice with human-like CMP-Neu5Ac hydroxylase deficiency. FASEB J. 25 (2011), 1887–1893.
96. Suzuki, A., Genetic basis for the lack of N-glycolylneuraminic acid expression in human tissues and its implication to human evolution. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 82 (2006), 93–103.
97. Kawano, T., et al. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid. J. Biol. Chem. 270 (1995), 16458–16463.
98. Matagne, A., et al. The beta-lactamase cycle: a tale of selective pressure and bacterial ingenuity. Nat. Prod. Rep. 16 (1999), 1–19.
99. Walsh, T.R., et al. Metallo-beta-lactamases: the quiet before the storm?. Clin. Micr. Rev. 18 (2005), 306–325.
100. Patel, G., Bonomo, R.A., Stormy waters ahead”: global emergence of carbapenemases. Front. Microbiol. 14 (2013), 4–48.
101. Shahid, M., et al. Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update. Crit. Rev. Microbiol. 35 (2009), 81–108.
102. Ehmann, D.E., et al. Kinetics of avibactam inhibition against class A, C and D β-lactamases. J. Biol. Chem. 288 (2013), 27960–27971.
103. Palzkill, T., Metallo-β-lactamase structure and function. Ann. N. Y. Acad. Sci. 1277 (2013), 91–104.
104. Galleni, M., et al. Standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother. 45 (2001), 660–663.
105. Gutkind, G.O., et al. Beta-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview. Curr. Pharm. Des. 19 (2013), 164–208.
106. Johnson, A.P., Woodford, N., Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J. Med. Microbiol. 62 (2013), 499–513.
107. Schenk, G., et al. Binuclear metallohydrolases: complex mechanistic strategies for a simple chemical reaction. Acc. Chem. Res. 45 (2012), 1593–1603.
108. Poeylaut-Palena, A.A., A minimalistic approach to identify substrate binding features in B1 Metallo-beta-lactamases. Bioorg. Med. Chem. Lett. 17 (2007), 5171–5174.
109. Faridoon, UI Islam, N., An update on the status of potent inhibitors of metallo-β–lactamases. Sci. Pharm. 81 (2013), 309–327.
110. Buynak, J.D., β-Lactamase inhibitors: a review of the patent literature (2010-2013). Expert. Opin. Ther. Pat. 23 (2013), 1469–1481.
111. Sievers, F., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol., 7, 2011, 539.
112. Finn, R.D., et al. Pfam protein families database. Nucl. Acids Res. 42 (2014), 222–230.
113. Baier, F., et al. Distinct metal isoforms underlie promiscuous activity profiles of metalloenzymes. ACS Chem. Biol. 10 (2015), 1684–1693.
114. Feng, H., et al. Structural and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins. J. Am. Chem. Soc. 136 (2014), 14694–14697.
115. Cordell, P.A., et al. The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II. J. Biol. Chem. 279 (2004), 28653–28661.
116. Touzot, F., et al. Function of Apollo (SNM1B) at telomere highlighted by a splice variant identified in a patient with Hoyeraal-Hreidarsson syndrome. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 10097–10102.
117. Pannicke, U., et al. Functional and biochemical dissection of the structure-specific nuclease ARTEMIS. EMBO J. 23 (2004), 1987–1997.
118. Ege, M., et al. Omenn syndrome due to ARTEMIS mutations. Blood 105 (2005), 4179–4186.